EORTC protocol 62091 - TRUSTS

TRUSTS : A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Trial StatusRecruitment suspended
DatesDate of activation: 27-May-11
Data management at EORTCFull
Phase2-3
Randomized trialYes
TypeAdvanced
Targeted Sample sizeEORTC Groups: 250 - All Groups: 370
Number of steps1
DrugDoxorubicin
Trabectedin
Study StaffBinh Bui-Nguyen (Study Coordinator) - Institut Bergonie, Bordeaux
Saskia Litiere (Statistician) - EORTC Headquarters, Brussels
Axelle Nzokirantevye (Data Manager) - EORTC Headquarters, Brussels
Sandrine Marreaud (Coordinating Physician) - EORTC Headquarters, Brussels
Anne Kirkpatrick (Project Manager) - EORTC Headquarters, Brussels, anne.kirkpatrick( at )eortc.be, +32 27741691
Gloria Montanes (Clinical Research Associate) - EORTC Headquarters, Brussels
Type of cancerSoft Tissue and Bone Sarcoma
Participating GroupsEORTC Soft Tissue and Bone Sarcoma Group(Coordinating Group)
Sarcoma Alliance for Research through Collaboration
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT01189253
EudraCT2009-014889-26
Protocol documents in PDF
(requires password)
Study documentation
Back to Protocol section